Blue Water to Partner on Development of Novel Monkeypox and Marburg Vaccine

 Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced a collaboration with AbVacc, Inc. (“AbVacc”) for the joint development of vaccine candidates targeting monkeypox and Marburg virus disease (“MVD”).

Both candidate vaccines will utilize BWV’s norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform, which allows for the presentation of multiple antigens on the surface of either the S or P particle of a norovirus backbone. BWV previously announced plans to explore a novel monkeypox vaccine candidate using this platform and under this agreement, AbVacc & BWV plan to work collaboratively to optimize the vaccine design and conduct preclinical immunogenicity and efficacy studies. In addition to monkeypox vaccine development, AbVacc will utilize its extensive expertise in MVD to develop a novel vaccine targeting Marburg virus using BWV’s VLP platform.

AbVacc, a recent spin-off of Integrated BioTherapeutics Inc. (“IBT”) developing rationally designed vaccines and monoclonal antibodies, is currently developing a monoclonal antibody for treatment of MVD, IBT-T03, with discovery and preclinical development supported by multiple government grants. In May 2021, IBT was awarded a $16.3M contract from the National Institute of Allergy and Infectious Diseases to support manufacturing and a Phase 1 clinical trial for IBT-T03H. Leveraging this background in MVD, AbVacc & BWV will seek to identify Marburg antigens to be presented within BWV’s VLP platform and optimize a potential vaccine candidate.

https://finance.yahoo.com/news/blue-water-vaccines-announces-partnership-141500690.html

Celsius publishes list of users eligible to withdraw majority of assets

 Bankrupt cryptocurrency lending firm Celsius had come up with a withdrawal process for users who had their crypto in its custody when it stopped withdrawals in June 2022.

Celsius released an official update on upcoming withdrawals on Jan. 31, providing the list of users eligible to withdraw approximately 94% of qualified custody assets.

The firm laid out the process in a 1,411-page court filing with the United States Bankruptcy Court for the Southern District of New York, listing the full names of all the eligible users alongside the type and amount of debted crypto assets.

Celsius stressed that eligible users would be asked to update their Celsius account with certain required information before any withdrawals are processed. The requested information includes customer data related to Anti-Money Laundering and Know Your Customer policies, as well as details about the destination address of the withdrawal, Celsius said, adding:

“Unless and until an eligible user updates his or her account with the required account updates, such eligible user will be unable to withdraw his or her distributable custody assets from the debtors' platform.”

 

The filing also notes that it’s not yet known whether eligible users will be able to withdraw the remaining 6% of the assets as the court will make a decision regarding this question at a later date.

Eligible users will also receive specific details related to gas and transaction fees associated with the upcoming withdrawal procedures. “Eligible users who do not have sufficient assets in their accounts to satisfy these fees will not be permitted to withdraw their assets,” Celsius wrote.

The news comes amid Celsius’s court-appointed examiner submitting a court filing on certain aspects of operations at the lender, including details about its complex dealings with the collapsed FTX exchange. The examiner report also revealed that Celsius used the accounting software Quickbooks to keep track of its finances, just like FTX and Alameda Research did.

Court-appointed examiner Shoba Pillay also wrote that Celsius and its founder Alex Mashinsky did not deliver on their promises surrounding its native Celsius 

CEL

$0.58

 token and other business activities.

https://cointelegraph.com/news/celsius-publishes-list-of-users-eligible-to-withdraw-majority-of-assets

Invacare files under Chapter 11

Refinancing action will reduce net debt by approximately 65%

Global manufacturing and delivery of products to continue uninterrupted to meet robust customer demand

Strong sequential improvement achieved in preliminary 4Q22 financial results

Executed strategic actions accelerating a renewed focus on core businesses

https://finance.yahoo.com/news/invacare-corporation-takes-action-strengthen-133300396.html

FDA OKs Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE

 Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Modulight Corporation ("Modulight"), a biomedical laser company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s VISUDYNE® (verteporfin for injection) photodynamic therapy (PDT) for the treatment of patients with predominantly classic subfoveal choroidal neovascularization, or the creation of abnormal choroidal blood vessels, due to Age-related Macular Degeneration (AMD).1 ML6710i is expected to be available for eye care professionals during the first half of 2023.

https://finance.yahoo.com/news/bausch-lomb-modulight-announce-fda-120000831.html

Evelo skin disease drug trial disappoints

 Evelo Biosciences Inc said on Wednesday its skin disease treatment did not meet the main goal in a mid-stage trial, and added it would reduce its workforce to conserve cash amid macroeconomic concerns.

The drug developer had 122 full-time employees, as of March 2022. Evelo did not disclose details on how many jobs it plans to cut.

Evelo said the drug, EDP1815, had failed to reduce the size and severity of eczema in the first three patient groups of the mid-stage trial.

The company was testing the drug on patients with atopic dermatitis and said it plans to wait for data from the final patient group in the study to make a decision on the drug.

https://finance.yahoo.com/news/1-evelo-biosciences-cut-jobs-130402304.html

Tonix to Work with UM, Baltimore, on Prevention of Rejection in Heart Xenograft Transplantation

 Research Study to Assess the Role of TNX-1500 in the Prevention of Heart Xenograft Rejection

Preclinical Xenotransplantation Studies are Expected to Support Regulatory Filings for TNX-1500

https://finance.yahoo.com/news/tonix-pharmaceuticals-announces-research-agreement-120000936.html

Boston Scientific FOURTH QUARTER AND FULL YEAR 2022

 Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for the period, which includes an approximate $0.04 negative impact of the Italian payback, compared to $0.45 a year ago.

https://finance.yahoo.com/news/boston-scientific-announces-results-fourth-113000374.html